Althea Jordan sits in her white recliner while her physical therapist, Danielle Heltzel, kneels on the floor in front of her ...

ASN-90 is under clinical development by Asceneuron and currently in Phase I for Alzheimer’s Disease. According to GlobalData, Phase I drugs for Alzheimer’s Disease have a 63% phase transition success ...

Foralumab is under clinical development by Tiziana Life Sciences and currently in Phase III for Secondary Progressive Multiple Sclerosis (SPMS).

Eli Lilly and Novo Nordisk are likely to introduce its popular injectable drugs semaglutide and tirzepatide in India in 2025.

The small miracles that 2024 brought to our lives lay the groundwork for new revolutionary treatments that are being prepared ...

About seven million people in the U.S. are living with Alzheimer’s disease, according to the Alzheimer’s Association. But ...

Microglia have been revealed to first help spread Alzheimer’s disease pathology across the brain and then activate to limit ...

Learn all the strategies and approaches when caring for dementia at home. There is support to help caregivers cope with the challenges they face along their caregiving journey ...

Higher levels of societal inequality are linked to reduced brain volume and disrupted connectivity, contributing to increased ...

The daily medication, called hydromethylthionine mesylate (HMTM), was developed by British firm TauRX in Aberdeen ...

A ‘GAME-changing’ drug which could slow down Alzheimer’s disease is being considered for potential use on the NHS. The daily medication, called hydromethylthionine mesylate ...

Researchers at New York-based Advanced Science Research Center of the CUNY Graduate Center (CUNY ASRC) have identified a crucial mechanism that connects cellular stress in the brain to the progression ...